Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety.

about

Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety.

Item

http://www.wikidata.org/entity/Q47813600

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Network meta-analysis of secon ...... arcinoma: efficacy and safety.

@en

Network meta-analysis of secon ...... arcinoma: efficacy and safety.

@nl

type

Item

label

Network meta-analysis of secon ...... arcinoma: efficacy and safety.

@en

Network meta-analysis of secon ...... arcinoma: efficacy and safety.

@nl

prefLabel

Network meta-analysis of secon ...... arcinoma: efficacy and safety.

@en

Network meta-analysis of secon ...... arcinoma: efficacy and safety.

@nl

P1476

Network meta-analysis of secon ...... arcinoma: efficacy and safety.

@en

P2093

Alexandre Peltier

http://www.w3.org/2001/XMLSchema#string

Bonaventure Banyurwabuke

http://www.w3.org/2001/XMLSchema#string

Elie El Rassy

http://www.w3.org/2001/XMLSchema#string

Fouad Aoun

http://www.w3.org/2001/XMLSchema#string

Joseph Kattan

http://www.w3.org/2001/XMLSchema#string

Marc Zanaty

http://www.w3.org/2001/XMLSchema#string

Simone Albisinni

http://www.w3.org/2001/XMLSchema#string

Thierry Roumeguere

http://www.w3.org/2001/XMLSchema#string

P2860

Sorafenib in advanced clear-cell renal-cell carcinoma

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Advances in the meta-analysis of heterogeneous clinical trials I: The inverse variance heterogeneity model.

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.

Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma

Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.

Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.

P304

2709-2717

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.2217/FON-2017-0268

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ziad Bakouny

Ghassan Sleilaty

P577

2017-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29183164

http://www.w3.org/2001/XMLSchema#string